Inactive Instrument

CTI BioPharma Corp.

Equities

CTIC

US12648L6011

Biotechnology & Medical Research

CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6

December 02, 2021 at 04:31 pm EST

SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:
Event: JMP Securities Hematology & Oncology Summit
Date: Monday, December 6, 2021
Time: 3:40 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

(PRNewsfoto/CTI BioPharma Corp.)

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology--oncology-summit-on-monday-december-6-301436710.html

SOURCE CTI BioPharma Corp.

Latest news about CTI BioPharma Corp.

DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	23-06-26	MT
DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	23-06-26	MT
DRI Healthcare Trust Announces USD 54.8 Million Debt Repayment from CTI Biopharma Corp	23-06-26	CI
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	23-06-26
Sobi Wraps Up $1.7 Billion Acquisition of CTI BioPharma	23-06-26	MT
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Global BMI Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Biotechnology Select Industry Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index	23-06-26	CI
Swedish Orphan Biovitrum Completes Tender for CTI BioPharma	23-06-25	MT
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of CTI BioPharma Corp. from a group of shareholders.	23-06-25	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Dynamic Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Completeness Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Growth Index	23-06-23	CI

Chart CTI BioPharma Corp.

Duration

Period

More charts

Company Profile

CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.05%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.09%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+7.77%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.60%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	11.94B
MEDPACE HOLDINGS, INC.	+31.57%	11.66B
UNITED THERAPEUTICS CORPORATION	+7.21%	11.01B

Other Biotechnology & Medical Research